This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.
Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.
Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.
Q4 Earnings Scorecard and Analyst Reports for Microsoft, Thermo Fisher & Union Pacific
by Sheraz Mian
Today's Research Daily features Q4 scorecard and new research reports on Microsoft (MSFT), Thermo Fisher (TMO), Union Pacific (UNP) and others.
Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.
Here's Why You Should Retain Avanos Medical (AVNS) Stock Now
by Zacks Equity Research
Investor confidence is high in Avanos Medical (AVNS) stock, courtesy of its solid prospects.
Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.
Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.
Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.
Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.
Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.
BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test
by Zacks Equity Research
BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.
The Zacks Analyst Blog Highlights: Goldman Sachs, Applied Materials, Charles Schwab, Caterpillar and Abbott Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman Sachs, Applied Materials, Charles Schwab, Caterpillar and Abbott Lab
Here's Why You Should Retain DaVita (DVA) in Your Portfolio Now
by Zacks Equity Research
Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.
Zacks.com featured highlights include: Sanderson Farms, Abbott Lab, Caterpillar, CNA Financial and Acushnet Holdings
by Zacks Equity Research
Zacks.com featured highlights include: Sanderson Farms, Abbott Lab, Caterpillar, CNA Financial and Acushnet Holdings
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.
CEO Confidence of U.S. Corporates Hits 17-Year High: 5 Picks
by Nalak Das
It will be prudent to invest in stocks of U.S. corporate giants as these companies have robust business model and a powerful brand value. These are: GS, AMAT, SCHW, CAT and ABT.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $123.04 in the latest trading session, marking a -1.89% move from the prior day.
Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.
AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from the Nurse and Allied Solutions segment in the fourth quarter.
Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.
The Zacks Analyst Blog Highlights: Abbott Lab, SAP SE, Freeport-McMoRan, Kraft Heinz and American International Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, SAP SE, Freeport-McMoRan, Kraft Heinz and American International Group